Clinical trial condition

HER2

Explore clinical trials studying HER2. Study availability and eligibility vary by location and protocol.

16 public trials 8 recruiting studies

Refine in advanced search Browse all conditions

HER2 trial results

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871

Conditions: Brain Diseases, Brain Metastases From HER2 and Breast Cancer, Brain Metastases From Solid Tumors, +36 more
Locations: UCSD Moores Cancer Center La Jolla, California, United States

USC Norris Comprehensive Cancer Center Los Angeles, California, United States

University of Colorado Cancer Center Aurora, Colorado, United States

University of Miami Miami, Florida, United States

View all 53 locations

View Trial Details

Recruiting

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

NCT06828588

Conditions: Breast Diseases, Breast Neoplasms, Carcinoma, +27 more
Locations: Vanderbilt University Medical Center Nashville, Tennessee, United States

View Trial Details

Recruiting

Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy

NCT07506057

Conditions: Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +10 more
Locations: The First Affiliated Hospital of China Medical University Shenyang, Liaoning, China

View Trial Details

Recruiting

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

NCT07356544

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations: IRCCS "Giovanni Paolo II" Bari, BA, Italy

Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori" Meldola, FC, Italy

Arcispedale Sant'Anna Ferrara, FE, Italy

Ospedale Policlinico San Martino Genova, GE, Italy

View all 22 locations

View Trial Details

Recruiting

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562

Conditions: Advanced Solid Tumor, Adult, Bronchial Neoplasms, Carcinoma, Bronchogenic, +13 more
Locations: START Midwest Grand Rapids, Michigan, United States

NYU Langone New York, United States

Tennessee Oncology Nashville, Tennessee, United States

NEXT Oncology Texas Austin, Texas, United States

View Trial Details

Recruiting

Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment

NCT07285941

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +14 more
Locations: Zhe Jiang Cancer Hospital Zhejiang, China

View Trial Details

Recruiting

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

NCT07030569

Conditions: Breast Cancer, Breast Cancer Metastatic, Breast Cancer Stage IV, +18 more
Locations: Fondazione IRCCS Istituto Nazionale Tumori Milan, Italy

View Trial Details

Recruiting

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

NCT06762977

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3), HER2
Locations: Ospedale Di Summa-Perrino Brindisi, Italy

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale Naples, Italy

View Trial Details

Enrolling by Invitation

Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics

NCT07454941

Conditions: Carcinoma, Carcinoma, Transitional Cell, Diagnostic, +8 more
Locations: National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences Beijing Beijing, Chaoyang District, China

View Trial Details

Not Yet Recruiting

First-line Therapy With EGFR-TKI Combined With Trastuzumab Rezetecan for Advanced NSCLC Harboring EGFR Mutations Concomitant With HER2 Alterations

NCT07699952

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations: Not specified

View Trial Details

HER2

HER2 trial results

Related conditions